title: Hepatotoxicants induce cytokine imbalance in response to innate immune system.
abstract: In recent years, attention has been paid to innate immune systems as mechanisms to initiate or promote drug-induced liver injury (DILI). Kupffer cells are hepatic resident macrophages and might be involved in the pathogenesis of DILI by release of pro- and anti-inflammatory mediators such as cytokines, chemokines, reactive oxygen species, and/or nitric oxides. The purpose of this study was to investigate alterations in mediator levels induced by hepatotoxic compounds in isolated Kupffer cells and discuss the relation between balance of each cytokine or chemokine and potential of innate immune-mediated DILI. Primary cultured rat Kupffer cells were treated with hepatotoxic (acetaminophen, troglitazone, trovafloxacin) or non-hepatotoxic (pioglitazone, levofloxacin) compounds with or without lipopolysaccharide (LPS). After 24 hr treatment, cell supernatants were collected and various levels of mediators released by Kupffer cells were examined. Although hepatotoxicants had no effect on the LPS-induced tumor necrosis factor-alpha (TNF-α) secretion, they enhanced the release of pro-inflammatory cytokine interleukin-1 beta (IL-1β) and suppressed the anti-inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10) induced by LPS. These cytokine shifts were not associated with switching the phenotypes of M1 and M2 macrophages in Kupffer cells. In conclusion, the present study suggested that the levels of some specific cytokines are affected by DILI-related drugs with LPS stimulation, and imbalance between pro- and anti-inflammatory cytokines, induced by the up-regulation of IL-1β and the down-regulation of IL-6 or IL-10, plays a key role in innate immune-mediated DILI.
authors.affiliation: Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd.
authors.forename: Shima
authors.initials: S
authors.lastname: Goto
authors.forename: Jiro
authors.initials: J
authors.lastname: Deguchi
authors.forename: Naoki
authors.initials: N
authors.lastname: Nishio
authors.forename: Naruaki
authors.initials: N
authors.lastname: Nomura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Funabashi
mesh_terms: D000082:Acetaminophen / Q000633:toxicity*; D000818:Animals; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000276:immunology*; D018925:Chemokines / Q000378:metabolism; D002839:Chromans / Q000633:toxicity*; D016207:Cytokines / Q000378:metabolism*; D015536:Down-Regulation / Q000187:drug effects; D024841:Fluoroquinolones / Q000633:toxicity*; D007113:Immunity, Innate / Q000276:immunology*; D018836:Inflammation Mediators / Q000378:metabolism*; D016753:Interleukin-10 / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007728:Kupffer Cells / Q000276:immunology* / Q000378:metabolism; D008297:Male; D009287:Naphthyridines / Q000633:toxicity*; D009569:Nitric Oxide / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D045162:Thiazolidinediones / Q000633:toxicity*; D000077288:Troglitazone; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D018925:Chemokines; D002839:Chromans; D016207:Cytokines; D024841:Fluoroquinolones; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D009287:Naphthyridines; D017382:Reactive Oxygen Species; D045162:Thiazolidinediones; D016753:Interleukin-10; D009569:Nitric Oxide; D000082:Acetaminophen; C080163:trovafloxacin; D000077288:Troglitazone